aspen Healthcare. We Care.

Marketed by Aspen Pharmacare
www.aspenpharma.com
Medical Hotline 0800 118 089

The COPD Assessment Test (CAT)

gsk

The CAT has been designed to measure the impact of COPD* on a patient's health by enabling them to describe their symptoms more accurately. This will improve communication with their doctor and give a better understanding of the disease's true impact, allowing treatment to be better targeted and the patient's care to be optimised.[1,2]

COPD limits airflow in the lungs causing breathing difficulties that affect patients' health, quality of life and ultimately survival. Over 210 million people worldwide have the condition[3] and it causes around 250 deaths every hour, more than lung and breast cancer combined.[4,5] However, partly due to difficulties in describing and assessing its full impact, it can be sub-optimally managed, causing patients to suffer increased symptoms, risk of hospitalisation and disability.[6,7]

The items that form the CAT, which is designed for patients to complete themselves, were identified following many interviews with patients coupled with rigorous scientific methodology. A wide range of international experts in COPD, patient groups and professional societies also played a key role in its development.[1,2]

The CAT, which was funded by GlaxoSmithKline (GSK), is freely available for use at: www.CATestonline.org.

CAT
COPD Assessment Test™

References

1. Jones P, *et al*. Development and first validation of the COPD Assessment Test (CAT). Abstract 700144. Accepted for presentation at ERS 2009.
2. Jones P, *et al*. Development and first validation of the COPD Assessment Test. *Eur Respir J* 2009: **34**:648-54.
3. The World Health Organization. Media Centre; Chronic obstructive pulmonary disease (COPD). (Last accessed 8 August 2009). http://www.who.int/mediacentre/factsheets/fs315/en/).
4. The World Health Organization. The World Health Report 2002. Reducing risks, promoting healthy life. MDI.WHR.202.A.
5. Ferlay J, *et al*. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress, Lyon, 2004.
6. Confronting COPD in America: Executive Summary; http://www.aarc.org/resources/confronting_copd/exesum.pdf; last accessed 130409.
7. Wilkinson T *et al*. *Am J Respir Crit Care Med* 2004;**169**;1298–1303

NOVARTIS PHARMACEUTICALS

Launch of Onbrez® Breezhaler® 150 µg

Novartis South Africa is pleased to announce the launch of Onbrez® Breezhaler® 150 µg (dry powder inhalation capsules) effective from 1 March 2013.



onbrez

Product MCC Registration Number	NAPPI Code	Product Description	Schedule	SEP excl VAT	UTI Product Code	Barcode
44/10.2.1/0544	717402001	Onbrez® Breezhaler® 150µg Indacaterol maleate equivalent to indacaterol 150µg	S3	R 228.00	102003	6005534002814

For any queries please contact the Novartis Customer Support Line on 0861 929 929.

Bayer HealthCare

Xarelto® rivaroxaban
Simple Protection for More Patients

Bayer HealthCare Pharmaceuticals is excited to announce the launch of **XARELTO®** 15 and **XARELTO®** 20, in South Africa. Each **XARELTO®** 15 tablet contains 15 mg rivaroxaban and **XARELTO®** 20 tablet contains 20 mg rivaroxaban.

XARELTO® 15 and **XARELTO®** 20 **Indications**:

- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF).
- Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE).
- Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).

XARELTO® 15 and **XARELTO®** 20 **Dosage**:

- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF) **20 mg once a day**.
  For patients with CrCl of 30 – 50 ml/min, 15 mg once a day is recommended.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention of recurrent DVT and PE **15 mg twice a day for the first 21 days, followed by 20 mg once a day.**

There is no need for routine coagulation monitoring, frequent dose adjustments or dietary restrictions with **XARELTO®** 15 and **XARELTO®** 20.

Product name	Pack sizes	EAN code	NAPPI CODE	UTI PHARMA	SEP Excl VAT	SEP Incl VAT
XARELTO® 15 	42's	6006118001148	719859001	100767	R908.53	R1035.72
XARELTO® 20 	28's	6006118001186	719860001	100768	R605.68	R690.48

Should you require a local package insert or more information, please do not hesitate to contact us.
Anel Berning, Thrombosis Marketing Manager, Tel: 011 921 5021, Cell: 072 606 2006, Email: anel.berning@bayer.com
Lionel Dobell, Thrombosis Product Manager, Tel: 011 921 5048, Cell: 083 6916988, Email: lionel.dobell@bayer.com



WORLD ASTHMA DAY™

Asthma limits the full potential of millions of South Africans

NATIONAL ASTHMA
EDUCATION PROGRAMME

The NAEP is striving to improve the health and well being of people living with asthma and is here to help you with:

- Dissemination and Interpretation of accredited Asthma Treatment Guidelines
- Free asthma information
- Accredited education programmes for health professionals

Become a professional member today.
Encourage your patients to become members.

Tel: 0861 ASTHMA (278462) • Fax: 086 655 0809 • E-mail: naepr@netactive.co.za

www.asthma.co.za

SOUTH AFRICAN THORACIC SOCIETY

ALLSA